Calculation
P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Product sales1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 28, 2025 | 4.98 | = | 114.31 | ÷ | 22.97 | 22.97 | = | 28,610 | ÷ | 1,245,346,062 | |
Feb 23, 2024 | 3.40 | = | 73.55 | ÷ | 21.62 | 21.62 | = | 26,934 | ÷ | 1,245,774,616 | |
Feb 22, 2023 | 3.86 | = | 83.50 | ÷ | 21.64 | 21.64 | = | 26,982 | ÷ | 1,247,105,154 | |
Feb 23, 2022 | 2.85 | = | 61.35 | ÷ | 21.54 | 21.54 | = | 27,008 | ÷ | 1,253,886,724 | |
Feb 25, 2021 | 3.24 | = | 62.79 | ÷ | 19.38 | 19.38 | = | 24,355 | ÷ | 1,256,593,156 | |
Feb 25, 2020 | 4.00 | = | 70.10 | ÷ | 17.50 | 17.50 | = | 22,119 | ÷ | 1,263,636,656 | |
Feb 26, 2019 | 3.84 | = | 65.28 | ÷ | 16.99 | 16.99 | = | 21,677 | ÷ | 1,275,510,558 | |
Feb 27, 2018 | 4.10 | = | 80.36 | ÷ | 19.59 | 19.59 | = | 25,662 | ÷ | 1,309,967,781 | |
Feb 27, 2017 | 3.08 | = | 70.50 | ÷ | 22.92 | 22.92 | = | 29,953 | ÷ | 1,307,066,900 | |
Feb 24, 2016 | 3.80 | = | 89.36 | ÷ | 23.52 | 23.52 | = | 32,151 | ÷ | 1,366,845,691 | |
Feb 25, 2015 | 6.36 | = | 104.43 | ÷ | 16.43 | 16.43 | = | 24,474 | ÷ | 1,489,401,683 | |
Feb 25, 2014 | 11.95 | = | 83.95 | ÷ | 7.02 | 7.02 | = | 10,804 | ÷ | 1,538,252,914 | |
Feb 27, 2013 | 6.95 | = | 42.89 | ÷ | 6.17 | 6.17 | = | 9,398 | ÷ | 1,522,392,518 | |
Feb 23, 2012 | 4.22 | = | 22.58 | ÷ | 5.35 | 5.35 | = | 8,102 | ÷ | 1,514,630,722 | |
Feb 28, 2011 | 4.19 | = | 19.49 | ÷ | 4.65 | 4.65 | = | 7,390 | ÷ | 1,590,529,288 | |
Mar 1, 2010 | 6.64 | = | 23.76 | ÷ | 3.58 | 3.58 | = | 6,469 | ÷ | 1,806,757,972 | |
Feb 27, 2009 | 8.03 | = | 22.40 | ÷ | 2.79 | 2.79 | = | 5,085 | ÷ | 1,821,909,204 | |
Feb 27, 2008 | 10.90 | = | 21.90 | ÷ | 2.01 | 2.01 | = | 3,733 | ÷ | 1,857,740,064 | |
Feb 27, 2007 | 12.67 | = | 17.65 | ÷ | 1.39 | 1.39 | = | 2,588 | ÷ | 1,858,655,664 | |
Mar 3, 2006 | 15.36 | = | 15.03 | ÷ | 0.98 | 0.98 | = | 1,809 | ÷ | 1,849,138,544 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Gilead Sciences Inc. Annual Report.
- Share Price Trend
- The share price exhibited a general upward trend from 15.03 US$ in March 2006 to a peak of 104.43 US$ in February 2015. After this peak, the price showed a period of decline and volatility, dropping to 61.35 US$ by February 2022. Subsequently, there was a rebound, with the share price rising again to 114.31 US$ by February 2025. This pattern indicates phases of growth, market correction, and renewed investor confidence over the examined period.
- Sales per Share Development
- Sales per share rose steadily from 0.98 US$ in March 2006 to a high of 23.52 US$ in February 2016. After this peak, there was a slight decline and stabilization with values fluctuating between approximately 16.99 US$ and 22.97 US$ from 2018 to 2025. The overall increase over the years suggests growth in the company’s revenue generation capacity per share, although the decline after 2016 indicates potential challenges or market saturation affecting sales growth.
- Price-to-Sales (P/S) Ratio Analysis
- The P/S ratio demonstrated a significant decrease from a high of 15.36 in 2006 to a low of 2.85 in February 2022. This indicates that the share price growth over time was generally outpaced by sales per share growth, making the stock less expensive relative to its sales. However, after 2022, the P/S ratio rose again to 4.98 by 2025, reflecting a renewed premium on the stock price compared to sales, possibly due to improved market sentiment or anticipated future growth.
- Overall Insights
- The data reflects a company that experienced substantial increases in both share price and sales per share during the early to mid-period, especially up to 2015-2016. Following this, performance indicators show some stagnation and correction, with sales per share stabilizing and share price experiencing volatility. The P/S ratio suggests that the market initially valued the company at a high premium relative to sales but adjusted this valuation downward over time, only to increase it again toward the most recent years. These trends highlight phases of rapid growth, market reassessment, and renewed optimism.
Comparison to Competitors
Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 28, 2025 | 4.98 | 6.04 | 4.88 | 2.36 | 6.23 | 18.25 | 4.26 | 3.60 | 2.32 | 5.52 | 4.73 | 10.78 |
Feb 23, 2024 | 3.40 | 5.72 | 5.78 | 2.19 | 7.76 | 20.77 | 4.43 | 5.43 | 2.61 | 7.84 | 4.99 | 11.16 |
Feb 22, 2023 | 3.86 | 4.61 | 5.17 | 3.29 | 5.79 | 10.96 | 4.34 | 4.71 | 2.35 | 7.01 | 4.73 | 8.56 |
Feb 23, 2022 | 2.85 | 4.53 | 5.10 | 3.16 | 6.37 | 8.01 | 4.66 | 3.96 | 3.15 | 4.20 | 5.39 | 8.21 |
Feb 25, 2021 | 3.24 | 4.05 | 5.64 | 3.16 | 7.01 | 8.06 | 5.15 | 3.93 | 4.42 | 6.24 | 5.52 | 8.82 |
Feb 25, 2020 | 4.00 | 4.22 | 6.03 | 5.52 | 6.29 | 6.03 | 4.79 | 4.33 | 3.66 | 5.34 | 4.83 | 14.95 |
Feb 26, 2019 | 3.84 | 3.58 | 5.22 | 3.67 | 3.97 | 5.15 | 4.45 | 4.92 | 4.49 | 6.62 | 4.24 | 15.54 |
Feb 27, 2018 | 4.10 | 6.67 | 5.82 | 5.02 | 3.70 | 3.71 | 4.56 | 3.68 | 4.05 | 5.92 | 4.01 | 16.42 |
Feb 27, 2017 | 3.08 | 3.84 | 5.65 | 4.72 | 3.48 | 4.18 | 4.62 | 4.54 | 3.84 | 7.86 | 3.37 | 12.51 |
Feb 24, 2016 | 3.80 | 3.83 | 5.28 | 6.07 | 2.91 | 4.02 | 4.13 | 3.56 | 3.76 | 9.38 | 3.05 | 20.38 |
Feb 25, 2015 | 6.36 | 4.90 | 6.13 | 6.28 | 3.09 | 4.03 | 3.77 | 3.93 | 4.24 | 14.62 | 3.06 | 47.41 |
Feb 25, 2014 | 11.95 | 4.31 | 5.22 | 5.48 | 2.78 | 2.81 | 3.63 | 3.78 | 3.97 | 15.52 | 3.74 | 16.53 |
Feb 27, 2013 | 6.95 | 3.30 | 4.09 | 3.40 | 2.32 | 2.71 | 3.17 | 2.73 | 3.34 | 11.66 | 2.12 | 6.60 |
Feb 23, 2012 | 4.22 | — | 3.52 | 2.63 | 2.28 | 1.87 | 2.75 | 2.43 | 2.37 | 20.90 | 1.77 | 5.61 |
Feb 28, 2011 | 4.19 | — | 3.32 | 2.23 | 2.48 | 1.73 | 2.65 | 2.18 | 2.27 | 7.38 | 2.00 | 56.82 |
Mar 1, 2010 | 6.64 | — | 3.88 | 2.27 | 2.16 | 1.82 | 2.82 | 4.23 | 2.83 | 5.74 | 1.98 | 80.12 |
Feb 27, 2009 | 8.03 | — | 3.44 | 1.96 | 1.30 | 1.66 | 2.37 | 2.14 | 1.72 | 5.17 | 1.44 | 28.70 |
Feb 27, 2008 | 10.90 | — | 3.46 | 2.30 | 2.16 | 3.05 | 2.95 | 4.04 | 3.11 | 11.94 | 2.40 | 12.17 |
Feb 27, 2007 | 12.67 | — | 5.41 | 3.07 | 2.30 | 3.80 | 3.53 | 4.23 | 3.67 | 19.70 | 5.05 | 17.58 |
Mar 3, 2006 | 15.36 | — | 7.24 | 2.34 | 2.40 | 4.31 | 3.49 | 3.50 | 3.77 | 14.06 | 2.15 | 26.93 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Gilead Sciences Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Gilead Sciences Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 28, 2025 | 4.98 | 5.55 |
Feb 23, 2024 | 3.40 | 5.89 |
Feb 22, 2023 | 3.86 | 4.56 |
Feb 23, 2022 | 2.85 | 4.50 |
Feb 25, 2021 | 3.24 | 4.90 |
Feb 25, 2020 | 4.00 | 4.88 |
Feb 26, 2019 | 3.84 | 4.54 |
Feb 27, 2018 | 4.10 | 4.60 |
Feb 27, 2017 | 3.08 | 4.29 |
Feb 24, 2016 | 3.80 | 4.10 |
Feb 25, 2015 | 6.36 | 4.54 |
Feb 25, 2014 | 11.95 | 4.30 |
Feb 27, 2013 | 6.95 | 3.25 |
Feb 23, 2012 | 4.22 | 2.58 |
Feb 28, 2011 | 4.19 | 2.44 |
Mar 1, 2010 | 6.64 | 3.00 |
Feb 27, 2009 | 8.03 | 2.22 |
Feb 27, 2008 | 10.90 | 3.19 |
Feb 27, 2007 | 12.67 | 3.88 |
Mar 3, 2006 | 15.36 | 3.84 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Gilead Sciences Inc. | Health Care | |
---|---|---|
Feb 28, 2025 | 4.98 | 2.61 |
Feb 23, 2024 | 3.40 | 2.72 |
Feb 22, 2023 | 3.86 | 39,755.53 |
Feb 23, 2022 | 2.85 | 2.65 |
Feb 25, 2021 | 3.24 | 2.59 |
Feb 25, 2020 | 4.00 | 2.51 |
Feb 26, 2019 | 3.84 | 2.51 |
Feb 27, 2018 | 4.10 | 2.49 |
Feb 27, 2017 | 3.08 | 2.29 |
Feb 24, 2016 | 3.80 | 2.30 |
Feb 25, 2015 | 6.36 | 2.62 |
Feb 25, 2014 | 11.95 | 2.38 |
Feb 27, 2013 | 6.95 | 1.87 |
Feb 23, 2012 | 4.22 | 1.66 |
Feb 28, 2011 | 4.19 | 1.57 |
Mar 1, 2010 | 6.64 | 1.77 |
Feb 27, 2009 | 8.03 | 1.47 |
Feb 27, 2008 | 10.90 | 2.14 |
Feb 27, 2007 | 12.67 | 2.60 |
Mar 3, 2006 | 15.36 | 2.90 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).